Regeneron Pharmaceuticals Inc.
GPTKB entity
Properties (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:Alder_BioPharmaceuticals
Checkmate Pharmaceuticals |
| gptkbp:awards |
gptkb:Nobel_Prize_in_Physiology_or_Medicine_(2020)
|
| gptkbp:CEO |
gptkb:Leonard_Schleifer
|
| gptkbp:clinicalTrials |
Dupixent for asthma
COVID-19_treatment Eylea_for_diabetic_retinopathy Libtayo_for_skin_cancer |
| gptkbp:collaborations |
gptkb:National_Institutes_of_Health
gptkb:U.S._Department_of_Defense |
| gptkbp:employeeCount |
approximately 2,500
|
| gptkbp:focus |
monoclonal antibodies
|
| gptkbp:founded |
1988
|
| gptkbp:founder |
gptkb:Leonard_Schleifer
|
| gptkbp:headquarters |
gptkb:Tarrytown,_New_York
|
| https://www.w3.org/2000/01/rdf-schema#label |
Regeneron Pharmaceuticals Inc.
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:partnerships |
Sanofi
|
| gptkbp:products |
gptkb:Regen-Cov
gptkb:Eylea Dupixent |
| gptkbp:revenue |
$8.5 billion (2020)
|
| gptkbp:stockExchange |
gptkb:REGN
|